Sign in

    Kallum Titchmarsh • Morgan Stanley

    Kallum Titchmarsh's questions to Embecta Corp (EMBC) leadership

    Kallum Titchmarsh's questions to Embecta Corp (EMBC) leadership • Q2 2025

    Question

    Kallum Titchmarsh inquired about the underlying growth and demand dynamics for pen needles and syringes, the impact of U.S. customer inventory issues and store closures, and the expected revenue cadence for the remainder of the fiscal year.

    Answer

    CEO Devdatt Kurdikar explained that difficult year-over-year comparisons were driven by prior-year ERP go-lives and the timing of price increases. He noted that the impact from a retail partner's store closures has been prudently factored into guidance and is considered transitory. CFO Jake Elguicze added that the second half of the year is expected to be stronger, with low-single-digit constant currency revenue growth anticipated for Q3.

    Ask Fintool Equity Research AI

    Kallum Titchmarsh's questions to Embecta Corp (EMBC) leadership • Q1 2025

    Question

    Kallum Titchmarsh inquired about the expected performance of Embecta's three main product categories (pen needles, syringes, safety products) for fiscal 2025, given the lumpiness caused by prior ERP system implementations. He also asked for an update on the GLP-1 pen needle opportunity, specifically the progress in Germany and the outlook for expansion into other markets.

    Answer

    CEO Devdatt Kurdikar explained that Q1 performance was impacted by a Q4 2024 order pull-forward ahead of a potential port strike and the timing of ERP implementations. He stated that underlying market trends for each product category remain unchanged. CFO Jake Elguicze quantified these impacts, noting a ~$10 million headwind from the port strike pull-forward and a ~$6 million impact from the prior year's ERP timing. Regarding GLP-1s, Mr. Kurdikar noted that the larger opportunity lies in co-packaging with generic GLP-1 entrants, with active discussions underway with over ten potential partners, and more details will be shared at the May 2025 Analyst Day.

    Ask Fintool Equity Research AI

    Kallum Titchmarsh's questions to Embecta Corp (EMBC) leadership • Q4 2024

    Question

    Kallum Titchmarsh questioned the timing of the decision to discontinue the patch pump program, pointing out that the competitive landscape and high investment needs were known factors for some time. He also asked about any post-spin restrictions from BD that could impact future M&A or product development.

    Answer

    CEO Devdatt Kurdikar explained that the decision was made after achieving FDA clearance for the pump and then conducting a market check for monetization opportunities. When no viable options surfaced, the company acted promptly to reallocate capital. He clarified that while there are restrictions on using technology acquired from BD at spin-off, there are no restrictions on future M&A, and creating financial flexibility through debt paydown is the key to pursuing new opportunities.

    Ask Fintool Equity Research AI

    Kallum Titchmarsh's questions to iRhythm Technologies Inc (IRTC) leadership

    Kallum Titchmarsh's questions to iRhythm Technologies Inc (IRTC) leadership • Q1 2025

    Question

    Kallum Titchmarsh inquired why customers who switched to Zio AT during a competitor's market disruption have remained with iRhythm and how this expanded user base could impact the upcoming Zio MCT launch.

    Answer

    CEO Quentin Blackford attributed customer retention to their positive experience with Zio AT, highlighting superior features like the 14-day continuous wear patch. He explained that many customers, already using Zio Monitor, found the product better than anticipated and decided to stick with it. He believes this success creates a 'real right to win' for the new Zio MCT product but deferred setting specific expectations for its launch.

    Ask Fintool Equity Research AI

    Kallum Titchmarsh's questions to iRhythm Technologies Inc (IRTC) leadership • Q4 2024

    Question

    Kallum Titchmarsh requested an update on the remediation of the FDA's 483 observations, asking about the specific changes made, what remains outstanding, and the nature of the dialogue with the FDA.

    Answer

    CEO Quentin Blackford stated that the company is pleased with its progress, having completed the majority of remediation activities. The target for completing FDA-specific items is mid-2025, with broader internal improvements extending through year-end. He described communication with the FDA as mostly administrative, with iRhythm providing monthly updates and the FDA acknowledging receipt without significant follow-up questions. A third-party audit is set to begin in Q2.

    Ask Fintool Equity Research AI

    Kallum Titchmarsh's questions to iRhythm Technologies Inc (IRTC) leadership • Q3 2024

    Question

    Kallum Titchmarsh from Morgan Stanley inquired about the commercial aspirations for the BioIntelliSense licensing agreement, the timeline for a multi-sensor product, and potential expansion into the inpatient monitoring market.

    Answer

    CEO Quentin Blackford positioned the BioIntelliSense deal as a long-term strategic investment to create a multi-sensing platform. He highlighted the potential to disrupt the hospital-to-home setting, leveraging iRhythm's ambulatory expertise. He noted this product would follow the next-gen MCT and also supports the company's home sleep test ambitions.

    Ask Fintool Equity Research AI

    Kallum Titchmarsh's questions to Penumbra Inc (PEN) leadership

    Kallum Titchmarsh's questions to Penumbra Inc (PEN) leadership • Q1 2025

    Question

    Kallum Titchmarsh requested more clinical color on the early rollout of Bolt 6X for below-the-knee cases and asked if Thunderbolt's technology could offer advantages for targeting distal clot.

    Answer

    CEO Adam Elsesser reported that Bolt 6X is converting physicians from open surgery due to its speed and predictability, with adoption spreading via word-of-mouth. Regarding Thunderbolt, he noted it was trialed with catheters down to the RED 62 for mid-sized vessels, but whether it offers a benefit in the most distal vessels remains an open question.

    Ask Fintool Equity Research AI

    Kallum Titchmarsh's questions to Treace Medical Concepts Inc (TMCI) leadership

    Kallum Titchmarsh's questions to Treace Medical Concepts Inc (TMCI) leadership • Q4 2024

    Question

    Kallum Titchmarsh from Morgan Stanley asked for management's perspective on the Zimmer Paragon acquisition, specifically regarding potential short-term benefits from disruption and any expected long-term changes to the competitive landscape.

    Answer

    CEO John Treace provided a brief response, stating that the company did not have much to comment on at this point. He emphasized that Treace Medical is focused on executing its own business plan and will observe how the acquisition and integration play out in the market.

    Ask Fintool Equity Research AI

    Kallum Titchmarsh's questions to Alphatec Holdings Inc (ATEC) leadership

    Kallum Titchmarsh's questions to Alphatec Holdings Inc (ATEC) leadership • Q4 2024

    Question

    Kallum Titchmarsh asked for commentary on business trends in January and February, whether the company was comfortable with Q1 consensus revenue estimates, and if there were any unusual revenue cadence assumptions for the year.

    Answer

    J. Koning (Executive) declined to provide intra-quarter commentary but noted the company exited Q4 with strong momentum. He expressed reasonable comfort with the current Q1 consensus revenue estimate, acknowledging the historical Q4-to-Q1 seasonality which he believes is already captured in analyst models.

    Ask Fintool Equity Research AI

    Kallum Titchmarsh's questions to Inspire Medical Systems Inc (INSP) leadership

    Kallum Titchmarsh's questions to Inspire Medical Systems Inc (INSP) leadership • Q3 2024

    Question

    Kallum Titchmarsh from Morgan Stanley asked about the company's priorities for its strong cash balance, beyond the previously announced stock buyback. He also inquired about which performance metrics would be provided in 2025 and beyond, given the plan to stop reporting new center numbers.

    Answer

    CEO Tim Herbert said the company remains 'opportunistic' with its stock buyback plan, which has not yet been used, and will continue to evaluate investments that can grow therapy adoption. CFO Rick Buchholz detailed that for 2025, Inspire will guide on revenue, gross margin, and EPS. They will also continue to disclose U.S. sales territories and are considering disclosing the number of field clinical representatives to offer insight into commercialization.

    Ask Fintool Equity Research AI